Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00067951 · ClinicalTrials.gov registry record · Phase 3
A Study To Evaluate The Safety And Efficacy Of An Investigational Diabetes Drug In Poorly Controlled Type II Diabetics
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 190
- Enrollment target
NCT00067951 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 190 participants.
The verdict
NCT00067951, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 190 participants
- Enrollment target
Study Summary
The purpose of this research study is to determine if a new investigational diabetes drug is safe and effective in treating people who have Type II diabetes mellitus with very high HbA1c or FPG (fasting plasma glucose) levels. The HbA1c test, also called the hemoglobin A1c test or glycated hemoglobin test, is a measurement of the average amount of sugar in the blood over the last 2 to 3 months. FPG is a test that measures the amount of sugar in the blood after an 8 hour fast.
Interventions
- DRUG rosiglitazone/metformin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 190 participants |
| Start Date | 2003-10-17 |
| Est. Completion | 2004-11-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00067951
The ClinicalTrials.gov registry entry for NCT00067951 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 190 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which rosiglitazone/metformin is the first listed.
NCT00067951 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00067951 about?
NCT00067951 is a clinical study titled "A Study To Evaluate The Safety And Efficacy Of An Investigational Diabetes Drug In Poorly Controlled Type II Diabetics". The purpose of this research study is to determine if a new investigational diabetes drug is safe and effective in treating people who have Type II diabetes mellitus with very high HbA1c or FPG (fasting plasma glucose) levels. The HbA1c test, also called the hemoglobin A1c test or glycated hemoglobi...
What is the current status of trial NCT00067951?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 190 participants. The study started on 2003-10-17. Estimated completion is 2004-11-30.
What interventions are being tested in trial NCT00067951?
The interventions under investigation include: rosiglitazone/metformin (DRUG).
Who is sponsoring clinical trial NCT00067951?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.